EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Statins as Repurposed Anticancer Agents: Regulated Cell Death, the Tumor Immune Microenvironment, and the Translational Evidence Gap

Xu Zhou iD, Yizhang Chen iD, Hanxiao Hua iD, Bo Shen iD, Shuai Liang, Dong Hua iD

Drug Development Research · 2026-11 · 87 (7)

DOI: 10.1002/ddr.70388 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 20.09.2026. Verfasst von Xu Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Med…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Tumor Microenvironment, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 111 Literaturangaben. Gefördert von: 2024 "Wild Goose Array Talents" Discipline Leader Fund of Wuxi People's Hospital, 2025 "Wild Goose Array Talents" Discipline Leader Fund of Wuxi People's Hospital, 2020 "Taihu Lake Talent Program" Leading Experts (2020-2024) under the Medical Key Strategic Project of Wuxi Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Statins inhibit 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase (HMGCR) and reduce flux through the mevalonate pathway, which supplies both cholesterol and the non‐sterol isoprenoids required for prenylation of small GTPases. Because this pathway is frequently activated in cancer, statins have become one of the most intensively studied candidates for oncological drug repurposing. Preclinical work indicates that statins can lower the threshold for apoptosis, modulate autophagy in either a pro‐death or a cytoprotective direction, induce pyroptosis, and sensitize cells to ferroptosis, while also acting on CD8 + T cells, macrophages, dendritic cells, and cancer‐associated fibroblasts within the tumor microenvironment. Clinical evidence, however, remains discordant with the strength of these mechanistic claims: favorable observational associations are susceptible to immortal‐time bias, healthy‐user bias, and confounding by indication, and randomized trials have been largely neutral for tumor‐directed endpoints. This narrative review appraises the mechanistic, preclinical, and clinical literature using an explicit five‐tier evidence hierarchy, and treats two constraints as analytical tools rather than closing caveats: the pharmacological heterogeneity of individual statins, and the one‐to‐two order‐of‐magnitude gap between concentrations used in cancer‐cell experiments and free drug concentrations achievable in patients. We conclude that statins are biologically plausible but clinically unproven anticancer agents whose evaluation should proceed through biomarker‐selected, pharmacodynamically validated combination trials rather than unselected add‐on designs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsTumor MicroenvironmentAntineoplastic AgentsNeoplasmsDrug RepositioningRegulated Cell DeathHumansAnimalsTranslational Research, Biomedical

Stichwörter der Autor:innen

drug repurposingmevalonate pathwayregulated cell deathstatinstumor immune microenvironment

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.
  • Department of Radiation Oncology, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.

ORCID-Profile: Xu Zhou, Yizhang Chen, Hanxiao Hua, Bo Shen, Dong Hua

Förderung

  • 2024 "Wild Goose Array Talents" Discipline Leader Fund of Wuxi People's Hospital
  • 2025 "Wild Goose Array Talents" Discipline Leader Fund of Wuxi People's Hospital
  • 2020 "Taihu Lake Talent Program" Leading Experts (2020-2024) under the Medical Key Strategic Project of Wuxi Municipal Health Commission
  • 2021 "Taihu Lake Talent Program" Leading Experts (2020-2024) under the Medical Key Strategic Project of Wuxi Municipal Health Commission
  • Oncology - Wuxi Municipal Innovation Team (14th Five-Year Plan)

Zitieren

APA

Zhou, X., Chen, Y., Hua, H., Shen, B., Liang, S., & Hua, D. (2026). Statins as Repurposed Anticancer Agents: Regulated Cell Death, the Tumor Immune Microenvironment, and the Translational Evidence Gap. Drug Development Research, 87(7). https://doi.org/10.1002/ddr.70388

Vancouver

Zhou X, Chen Y, Hua H, Shen B, Liang S, Hua D. Statins as Repurposed Anticancer Agents: Regulated Cell Death, the Tumor Immune Microenvironment, and the Translational Evidence Gap. Drug Development Research. 2026;87(7). doi:10.1002/ddr.70388

BibTeX
@article{Zhou2026,
  author = {Zhou, Xu and Chen, Yizhang and Hua, Hanxiao and Shen, Bo and Liang, Shuai and Hua, Dong},
  title = {Statins as Repurposed Anticancer Agents: Regulated Cell Death, the Tumor Immune Microenvironment, and the Translational Evidence Gap},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {7},
  doi = {10.1002/ddr.70388}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche